surmount studies tirzepatide trials for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial SURMOUNT-1 Trial Tirzepatide for Obesity Treatment and

Some clinical studies have documented reductions in high-sensitivity C-reactive protein (hsCRP) among patients treated with tirzepatide for type 2 diabetes or obesity

The Big Picture: Where Tirzepatide Fits Among Weight Loss Medications Today there are six FDA-approved medications most commonly prescribed for chronic weight management: Tirzepatide (brand name Zepbound) weekly injection, FDA-approved for weight management in November 20234 Semaglutide (brand names Wegovy and Ozempic) weekly injection Liraglutide (brand name Saxenda) daily injection Phentermine (often combined with topiramate as Qsymia) daily oral pill Naltrexone-bupropion (brand name Contrave) daily oral pill Orlistat (brand names Xenical and Alli) oral capsule with meals In large clinical trials, the average percent body weight lost over 1218 months looks roughly like this:[1][1] Tirzepatide: about 20% Semaglutide: about 14% Phentermine/topiramate: about 9% Liraglutide: about 5% Naltrexone-bupropion: about 5% Orlistat: about 3% Tirzepatide is, on paper, the most effective

But the per-visit consultation fees and dose-dependent pricing can make long-term costs less predictable than flat-rate alternatives

Cyclic Vomiting Syndrome What It Is: Recurring episodes of severe vomiting with no apparent cause, potentially triggered or worsened by GLP-1 medications

Regular monitoring allows us to catch problems early when they're most treatable